Expression of homeobox A1 (HOXA1) results in oncogenic transformation of immortalized human mammary epithelial cells with aggressive tumor formation in vivo. However, the mechanisms by which HOXA1 mediates oncogenic transformation is not well defined. To identify molecules that could potentially be involved in HOXA1-mediated oncogenic transformation, microarray analysis was utilized to characterize and compare the gene expression pattern in response to forced expression or depletion of HOXA1 in human mammary carcinoma cells. Gene expression profiling identified that genes involved in the p44/42 mitogen-activated protein (MAP) kinase activation pathway (GRB2, MAP kinase kinase (MEK1) and SDFR1) or p44/42 MAP kinase-regulated genes (IER3, EPAS1, PCNA and catalase) are downstream expression targets of HOXA1. Forced expression of HOXA1 increased GRB2 and MEK1 mRNA and protein expression and increased p44/42 MAP kinase phosphorylation, activity and Elk-1-mediated transcription. Use of a MEK1 inhibitor demonstrated that increased p44/42 MAP kinase activity is required for the HOXA1-mediated increase in cell proliferation, survival, oncogenicity and oncogenic transformation. Thus, modulation of the p44/42 MAP kinase pathway is one mechanism by which HOXA1 mediates oncogenic transformation of the human mammary epithelial cell.
Introduction
Homeobox A1 (HOXA1) is a member of the homeodomain containing transcription factor family, which plays a pivotal role during the normal growth and differentiation of mammalian tissues. HOX genes exhibit distinct patterns of expression during development, and alterations in their expression have been linked to various diseases, including development of neoplasia (Chen and Sukumar, 2003) . In the human mammary gland, the expression of the HOXA1 gene is very low or absent during normal growth and differentiation, but is detectable in a variety of human breast cancer lesions (Chariot and Castronovo, 1996) . We have previously observed that forced expression of HOXA1 in immortalized human mammary epithelial cells MCF-10A, concomitantly enhances proliferation and cell survival, thus forming the basis for abnormal mammary acinar morphogenesis, oncogenic transformation and tumor formation in vivo. Use of a pharmacological inhibitor of B-cell leukemia/lymphoma-2 (Bcl-2) completely prevented anchorage-independent growth seen in MCF-10A cells overexpressing HOXA1 (Zhang et al., 2003) . However, the molecular mechanisms by which HOXA1 induces oncogenic transformation and promotes tumorigenicity of human mammary epithelial cells remains poorly understood.
Signalling through pathways involving mitogenactivated protein kinases (MAP kinases) has been implicated in the pathogenesis of cancer. The p44/42 MAP kinase pathway is a well-characterized intracellular signalling pathway that transduces signals from the cell surface to the nucleus to activate transcription. Activation of p44/42 MAP kinase occurs by dual phosphorylation of threonine and tyrosine residues (Seger and Krebs, 1995) . This activation is executed by an enzyme known as MAP kinase kinase. p44/42 MAP kinase has been demonstrated to be involved in various cellular processes, including cell proliferation, differentiation, apoptosis and oncogenic transformation. Constitutive activation of this signalling cascade has been noted in the oncogenic transformation of various cell lines, and increased p44/42 MAP kinase activity has been implicated in the metastatic potential of human cancer (Mansour et al., 1994) . The p44/42 MAP kinase activity level alone has been suggested to have prognostic significance for the survival of breast cancer patients (Mueller et al., 2000) . Additionally, an orally active inhibitor of MAP kinase kinase (MEK), PD184352, was observed to inhibit significantly the growth of colon carcinomas of both murine and human origin (SeboltLeopold et al., 1999) .
To elucidate the mechanisms by which HOXA1 induces oncogenic transformation of the human mammary epithelial cells, we evaluated the changes in gene expression in human breast carcinoma cells, MCF-7, in response to HOXA1. Oligonucleotide microarray analysis revealed that HOXA1 upregulates multiple components of the p44/42 MAP kinase pathway, resulting in increased p44/42 MAP kinase activity. This increased p44/42 MAP kinase activity mediates HOXA1-stimulated oncogenicity of human breast carcinoma cells and oncogenic transformation of immortalized human mammary epithelial cells.
Results

Microarray analysis identifies downstream determinants of HOXA1
To identify potential mechanisms by which HOXA1 may result in oncogenic transformation, we resorted to the use of the described microarray platform. Two complementary pairs of cell lines were utilized for these studies. The first was the well-characterized mammary carcinoma cell line (MCF-7) with forced expression of HOXA1 and as compared with the vector transfected control (Zhang et al., 2003) . Secondly, we generated a small interfering RNA (siRNA) construct of human HOXA1 to target endogenous HOXA1 mRNA for degradation (Zhu et al., 2005) and stably expressed this siRNA in MCF-7 cells. For control purposes, we utilized the same vector with a scrambled siRNA target sequence. The expression levels of these two paired cell lines were verified by reverse transcriptase-polymerase chain reaction (RT-PCR) analysis. MCF-7-HOXA1 demonstrated higher levels of HOXA1 mRNA when compared with that of MCF-7-vector, and MCF-7-HOXA1 siRNA demonstrated lower levels of HOXA1 mRNA when compared with MCF-7-scrambled-siRNA ( Figure 1a ). This was further verified by the analysis of HOXA1 transcriptional activity by use of the EphA2-r42B enhancer (Zhang et al., 2003) . MCF-7-HOXA1 cells exhibited increased HOXA1-mediated transcriptional activity when compared with MCF-7-vector cells, and MCF-7-HOXA1 siRNA demonstrated a lower level of HOXA1-mediated transcriptional activity when compared with the MCF-7-scrambled-siRNA ( Figure 1b) .
We subsequently used the RNA extracted from the two paired cell lines to perform microarray analyses to identify HOXA1-regulated genes. The aim of this approach was to improve specificity of the microarray output as only those genes with the appropriate directional regulation (i.e., increased expression with forced expression of HOXA1 and decreased expression with HOXA1 depletion or vice versa) were to be finally selected. Firstly, to identify genes regulated by forced expression of HOXA1 in mammary carcinoma cells, RNA from MCF-7-HOXA1 cells was hybridized to that of the MCF-7-vector cells. The expression level of each gene was represented by pseudocolor in matrix format, with red representing increasing mRNA levels and green denoting decreasing mRNA levels, and color intensity representing the magnitude of the expression ratio. As listed in Supplementary data Table 1 , microarray analysis identified 2450 genes that exhibited a 1.5-fold or greater change with forced expression of HOXA1. Among these, 1130 genes were upregulated and 1320 were downregulated. We next examined the changes in We subsequently compared the expression profiles from the two sets of paired cell lines to determine which genes were coordinately regulated and would therefore represent potential HOXA1 downstream effector molecules. Among 1130 upregulated genes in MCF-7 cells with forced expression of HOXA1, 424 corresponding genes were observed to exhibit decreased expression in MCF-7-HOXA1 siRNA compared with the MCF-7-scrambled-siRNA cell line. Of the 1320 genes with decreased expression upon forced expression of HOXA1, the expression of 260 corresponding genes increased in HOXA1-depleted cells. Thus, a total of 684 genes demonstrated concordant directional regulation between the two paired cell sets. This accounts for 28% of total differentially expressed genes in cells with forced expression of HOXA1 and 63% of that in the HOXA1-depleted cells. A hierarchical clustering algorithm based on Pearson correlation coefficients was applied to group genes on the basis of expression pattern similarity over two sets of expression profiles. The expression level of each gene was represented by pseudocolor in matrix format (Figure 2a) . Interestingly, the fold change of each gene in the intersecting regions of the Venn diagram in Figure 2a exhibited relatively similar magnitudes of expression in the appropriate direction. The correlation efficiencies between these two independent microarray experiments were significantly high, 0.89 for upregulated genes (Figure 2b ) and 0.60 for downregulated genes (Figure 2c ).
Functional classification of the differential responsive genes to HOXA1
To assess the potential functionality of genes regulated by HOXA1, the gene products were grouped into Gene Ontology (http://www.geneontology.org) categories with the assistance of Stanford SOURCE database (Diehn et al., 2003) . Of the 424 upregulated genes, 334 had known biological roles and of 260 downregulated genes, 140 had known biological roles. These genes were classified by broad biological function. They encode proteins that are involved in a broad range of cellular functions and metabolic pathways. The functions of these genes include regulation of apoptosis, biosynthesis, cell adhesion, cell cycle, development, DNA/RNA processing, metabolism, signal transduction, cellular structure, stress response, transcription regulation and cellular transport. Regulatory molecules involved in signal transduction, metabolism and biosynthesis comprised the bulk of the gene lists ( Figure 2d ). The genes with known or predicted functions are also presented in Supplementary data Tables 2 and 3 with fold change indicated.
p44/42 MAP kinase pathway candidate genes are upregulated by HOXA1 To obtain a more detailed understanding of the molecular mechanisms potentially utilized by HOXA1 to stimulate oncogenicity, we focused our analysis on components of specific pathways utilized for signal transduction. We initially observed from the HOXA1-regulated gene list that components of the p44/42 MAP kinase pathway were modulated by HOXA1. Indeed, we observed increased expression of several genes important in p44/42 MAP kinase-mediated signalling, implicating this pathway as a potential expression target of HOXA1. Supplementary data Table 4 represents 29 genes that are involved in the p44/42 MAP kinase pathway and regulation of their expression by HOXA1.
To verify the fidelity of data generated from the microarray analysis, we performed semiquantitative RT-PCR with the different microarray identified genes that activate, (SDFR1) regulate (GRB2 and MEK1) or are regulated (IER3, EPAS1, PCNA and catalase) by the p44/42 MAP kinase pathway. As observed in Figure 3a , forced expression of HOXA1 concomitantly increased the mRNA levels of GRB2, MEK1, SDFR1, IER3, EPAS1, PCNA and catalase. Similarly, with siRNA-mediated HOXA1 depletion in MCF-7 cells, the mRNA expression of each of these genes was decreased. Thus, HOXA1 specifically regulates the expression of genes directly involved in the p44/42 MAP kinase activation pathway, specifically GRB2 and MEK1.
The increased expression of GRB2 and MEK1, in response to increased expression of HOXA1, was further substantiated by Western blot analysis. MCF-7-HOXA1 cells exhibited higher expression of GRB2 and MEK1 protein as compared with the MCF-7-vector cell line ( Figure 3b ). Similarly, expression of both GRB2 and MEK1 protein was decreased in MCF-7 cells with siRNA-mediated depletion of HOXA1 (Figure 3b) . Thus, components of the p44/42 MAP kinase activation pathway are downstream expression targets of HOXA1.
To determine whether HOXA1 expression would broadly correlate with expression of MEK1, we performed similar semiquantitative RT-PCR experiments on RNA extracted from a variety of mammary epithelial and mammary carcinoma cells. As illustrated in Figure 3c , there was a tight correlation between HOXA1 and MEK1 mRNA expression in 9 of the 12 cell lines tested for both genes, the exceptions being the T47D, MDA-MB-231 and MDA-MB-468 cell lines. This suggests that HOXA1 is one of the major regulators of MEK1 expression in mammary carcinoma cells.
p44/42 MAP kinase activity is increased by forced expression of HOXA1 As HOXA1 increased expression of components of the p44/42 MAP kinase activation pathway, it could be expected that forced expression of HOXA1 would also result in increased activity of p44/42 MAP kinase. The activation of p44/42 MAP kinase by various growth factors has previously been demonstrated to require dual phosphorylation on threonine and tyrosine (Thr202 and Tyr204) (Seger and Krebs, 1995) . We, therefore, examined for activated p44/42 MAP kinase in MCF-7 cells with forced expression of HOXA1, and in cells with siRNA-mediated depletion of HOXA1, using an antibody that specifically recognizes dual phosphorylated p44/42 MAP kinase (phospho-ERK1/2). We observed that neither forced expression nor siRNAmediated depletion of HOXA1 influenced total p44/42 MAP kinase protein expression. However, the level of dual phosphorylated p44/42 MAP kinase was higher with forced expression of HOXA1 compared with that of vector-transfected control cells (Figure 4a ). Consistent with this, the level of dual phosphorylated p44/42 MAP kinase was lower in MCF-7 cells with siRNAmediated depletion of HOXA1 compared with that of scrambled-siRNA vector-transfected control cells (Figure 4a ). To verify this observation, we also examined the effect of HOXA1 on actual p44/42 MAP All four different stable cell lines were grown to 60-80% confluence and were transiently transfected with the Elk promoter-luciferase construct in serum-free (b) and serum conditions (c). Cells were processed for luciferase assay as described in 'Materials and methods'. The same procedure was followed for Egr-3 luciferase construct in serum free (d) and serum conditions (e). Results represent mean of triplicate determinations; bars, s.d. *Po0.001. kinase activity by assessing the in vitro activity of p44/42 MAP kinase activity in MCF-7-HOXA1 and MCF-7-HOXA1 siRNA cells compared with their respective controls. Concordant with the level of p44/42 MAP kinase phosphorylation, we observed that increased expression of HOXA1 significantly increased p44/42 MAP kinase activity, whereas decreased HOXA1 expression resulted in decreased p44/42 MAP kinase activity (Figure 4a) . HOXA1, therefore, regulates p44/ 42 MAP kinase activity in human mammary carcinoma cells.
HOXA1 activates Elk-1-mediated transcription
Increased phosphorylation and activity of p44/42 MAP kinase will result in transcriptional activation of downstream effector molecules. One mechanism by which p44/42 MAP kinase regulates transcriptional activation is by use of Elk-1-mediated transcription (Gille et al., 1995) . Elk-1-mediated luciferase activity was increased almost sixfold by forced expression of HOXA1 and decreased to 63% by HOXA1 depletion when compared with that of the respective vector control in serum-free medium (Figure 4b ). Stimulation with serum similarly resulted in an almost sixfold increase of Elk-1-mediated transcription by forced expression of HOXA1 compared with control, and Elk-1-mediated transcription was decreased to 70% by depletion of endogenous HOXA1 expression compared with control ( Figure 4c) .
We have further validated the effect of altered HOXA1 expression on Elk-1 transcriptional activation by use of the Egr-3 luciferase reporter construct to examine p44/42 MAP kinase-mediated transcriptional activation. The Egr-3 luciferase reporter construct contains a luciferase coding sequence, downstream of an Egr-1 promoter fragment, comprising 624 bp 5 0 of the initiation codon. This 624 bp Egr-1 promoter fragment possesses five SRF/Ets response elements, that are responsive to p44/42 MAP kinase stimulation through phosphorylation of Elk-1 and Sap1a (Clarkson et al., 1999) , We observed a 45-fold increase in Elk-1-and Sap1a-mediated transcription with forced expression of HOXA1, and a decrease to 67% in HOXA1-depleted cells compared with their respective vector controls in serum-free condition (Figure 4d ). In the presence of serum, Elk-1-and Sap1a-mediated transcription was increased 12-fold upon forced expression of HOXA1, and it decreased to 16% by siRNA-mediated depletion of HOXA1 (Figure 4e) . HOXA1, therefore, regulates p44/42 MAP kinase-mediated transcription in human mammary carcinoma cells.
HOXA1-stimulated cellular proliferation and survival is p44/42 MAP kinase-mediated
Given the pivotal role of p44/42 MAP kinase activity in oncogenic transformation (Mansour et al., 1994) , it is plausible that HOXA1 increased p44/42 MAP kinase activity mediates HOXA1-stimulated oncogenicity of human mammary carcinoma cells. To address this, we utilized the MEK1 inhibitor, PD098059, to assess whether the HOXA1-stimulated increase in total mammary carcinoma cell number (Zhang et al., 2003) is mediated by p44/42 MAP kinase. As shown in Figure 5a , the HOXA1-stimulated increase in mammary carcinoma cell number was largely prevented by PD098059. Increase in total mammary carcinoma cell number, stimulated by HOXA1, is consequent on increases in both cell proliferation and cell survival (Zhang et al., 2003) , albeit the proliferative effect stimulated by HOXA1 is minimal. The p44/42 MAP kinase dependence of HOXA1-stimulated proliferation was, therefore, determined by incorporation of 5 0 -bromo-2 0 -deoxyuridine (BrdU) during entry to S phase. PD098059 prevented the HOXA1-stimulated increase in BrdU incorporation in mammary carcinoma cells as shown in Figure 5b . Thus, HOXA1-stimulated increases in human mammary carcinoma cell proliferation is p44/ 42 MAP kinase dependent.
We next examined the dependence of HOXA1-stimulated cell survival on p44/42 MAP kinase activity. As observed in Figure 5c , forced expression of HOXA1-protected mammary carcinoma cells from apoptosis due to serum deprivation and exposure of cells to PD098059 abolished this protective effect of HOXA1. We have previously demonstrated that forced expression of HOXA1 in mammary carcinoma cells resulted in decreased apoptotic cell death mediated by a specific increase in Bcl-2 (Zhang et al., 2003) . Thus, HOXA1 may utilize p44/42 MAP kinase to mediate upregulation of Bcl-2 required for cell survival. We examined the effect of inhibition of p44/42 MAP kinase on the HOXA1-stimulated increase in Bcl-2 mRNA. Concordant with previous observation, MCF-7-HOXA1 cells exhibited higher Bcl-2 mRNA in comparison with MCF-7-vector cells in serum-free media ( Figure 5d ). As observed in Figure 5d , the HOXA1-stimulated upregulation of Bcl-2 mRNA was significantly reduced by treatment with PD098059. Thus, the HOXA1-stimulated increases in Bcl-2 expression and cell survival is p44/42 MAP kinase dependent.
HOXA1-mediated oncogenicity is p44/42 MAP kinase-dependent
Anchorage-independent growth is one characteristic feature of oncogenically transformed cells. This process can be simulated in vitro by measurement of the cell's ability to grow independently of substrate adhesion and to form colonies on a soft agar (Shin et al., 1975) . Forced expression of HOXA1 in mammary carcinoma cells significantly increased the number of colonies formed on soft agar compared with control ( Figure 6a ) in accord with the previous demonstration that HOXA1 increases oncogenicity (Zhang et al., 2003) . The ability of HOXA1 to stimulate the formation of colonies on soft agar was significantly reduced by treatment with PD098059 (Figure 6a ). We verified this further by use of suspension culture, another measure for anchorage-independent growth (Figure 6b) . Thus, the HOXA1-stimulated increase in oncogenicity of human mammary carcinoma cells is p44/42 MAP kinase-dependent.
Forced expression of HOXA1 has also been demonstrated to result in de novo oncogenic transformation of immortalized human mammary epithelial cells (Zhang et al., 2003) . We, therefore, stably transfected immortalized human mammary epithelial cells (MCF-10A) with pCMV Tag2B vector (MCF-10A-vector) or the vector containing HOXA1 cDNA (MCF-10A-HOXA1). The expression levels of these stable cell lines were verified by RT-PCR analysis and HOXA1-mediated transcriptional activity. The MCF-10A-HOXA1 stable cell line exhibited higher levels of HOXA1 mRNA and HOXA1-mediated transcriptional activity when compared with MCF-10A-vector (Figure 6c and d) .
To determine whether HOXA1-stimulated oncogenic transformation per se was dependent on p44/42 MAP kinase activity, we examined the ability of PD098059 to prevent soft agar colony formation in MCF-10A cells consequent on forced expression of HOXA1. As expected, forced expression of HOXA1 in MCF-10A cells produced colonies in soft agar, whereas the control vector-transfected cells exhibited only a small number of spontaneously formed colonies (Figure 6e ), as described previously. As observed in Figure 6e , use of PD098059 completely prevented HOXA1-stimulated soft agar colony formation by the MCF-10A-immortalized human mammary epithelial cell line. Thus, p44/42 MAP kinase mediates HOXA1-induced oncogenic transformation of human mammary epithelial cells.
When cultured in a reconstituted basement membrane (Matrigel), immortalized human mammary epithelial cells undergo a series of morphogenetic processes, resulting in the formation of acinus-like structures containing a single layer of polarized cells surrounding a hollow lumen. Formation of the luminal space in this model follows the development of apico-basal polarity, and involves apoptosis and an autophagy-like process in the centrally localized cells (Debnath et al., 2003) . In contrast, oncogenically transformed mammary epithelial cells form large, non-polarized, undifferentiated colonies without lumina when grown in matrigel (Zhu et al., 2005) . We used this ex vivo model to examine potential disruptive effects of HOXA1 on the architecture of acinar structures formed by immortalized human mammary epithelial cells. Three-dimensional (3D) acinar structures were generated by plating MCF-10A cells as single cells in matrigel. Confocal laser scanning microscopic analyses of acini, labelled with basal surface marker (a6 integrin) and apical polarity marker (GM130), indicated that the acini formed consisted of polarized mammary epithelial cells and a hollow lumen (Figure 7a ). Forced expression of HOXA1 in immortalized human mammary epithelial cells resulted in the generation of large disorganized multi-acinar structures with filled lumina, and also disrupted cellular polarization (Figure 7b ). Fifty-eight percent of the formed acinar structure in MCF-10A-HOXA1 exhibit large disorganized multiacinar structure with filled lumina (Figure 7c ). After treatment with MEK1 inhibitor, only 14% of MCF-10A-HOXA1 cells formed large multiacinar structures and the majority of acini possessed a lumen (Figure 7d and e). HOXA1, therefore, specifically utilizes p44/42 MAP kinase for execution of its oncogenic program.
Discussion
Dysregulated expression of many HOX genes has been shown to be involved in the oncogenic process (Chen and Sukumar, 2003) . Owing to the simplicity of core binding motifs for HOX genes (such as ATTA) that are present in many potential HOX target genes promoters, delineation of the mechanism of action of HOX genes in neoplasia is complex. We had previously demonstrated that forced expression of HOXA1 in immortalized human mammary epithelial cells resulted in an increase in cell number, primarily by the promotion of cell survival, mediated by the transcriptional upregulation of Bcl-2 (Zhang et al., 2003) . Here, we have used oligonucleotide microarray analysis to identify expression targets of HOXA1 in human mammary carcinoma cells and identified components of the p44/42 MAP kinase pathway as one major effector of HOXA1-mediated oncogenicity and oncogenic transformation. The genome-wide analyses performed here demonstrated that HOXA1 upregulated the expression of genes that are downstream of the p44/42 MAP kinase pathway. Expression targets of HOXA1 include PCNA, SDFR1, IER3 and EPAS1 genes that are involved in cell cycle regulation, angiogenesis and proliferation. One of the upregulated genes, SDFR1, a chemokine receptor, has been shown to activate p44/42 MAP kinase pathway during astrocyte proliferation (Bajetto et al., 2001) . Another upregulated gene, IER3 (IEX-1), is an immediate upstream regulator that potentiates p44/42 MAP kinase activation in response to growth factors and is also involved in the regulation of cell death and oncogenesis (Garcia et al., 2002) . In MCF-12A mammary epithelial cells, constitutive activation of p44/42 MAP kinase pathway also results in transcriptional upregulation of IER3 (Grill et al., 2004) . Endothelial PAS-domain protein 1 (EPAS1) is phosphorylated by p44/42 MAP kinase pathway, and is also involved in angiogenesis of human renal carcinoma (Conrad et al., 1999) . Proliferating cell nuclear antigen (PCNA) has a pivotal role in the regulation of cell growth, acts as a prognostic factor of metastasis in breast cancer and is a substrate of p44/42 MAP kinase (Yu et al., 2005) . The level of PCNA correlates directly with the rates of cellular proliferation and DNA synthesis (Prosperi, 1997) . Previously, we have also reported that p44/42 MAP kinase-mediated upregulation of catalase results in inhibition of oxidative stress-induced apoptosis in human mammary carcinoma cells. Thus, p44/42 MAP kinase-mediated upregulation of catalase by HOXA1 may offer similar protection from oxidative stress (Zhu et al., 2005b) . The p44/42 MAP kinase pathway is a major pathway involved in cell proliferation and survival. Activation of the MAP kinase pathway has been demonstrated to be a frequent event in tumorigenesis (Mansour et al., 1994) . Analysis of human breast carcinomas demonstrates that 25-50% of these tumors express elevated levels of phosphorylated p44/42 MAP kinase (Salh et al., 1999) . Previous studies have also reported that activation of the p44/42 MAP kinase pathway intermediate MEK1, regulated by HOXA1 herein, is sufficient to transform several cell types. Although GRB2 does not have transforming potential when overexpressed (Cheng et al., 1998) , early studies demonstrated that GRB2 overexpression could amplify activation of Ras or p44/42 mitogen-activated protein kinase (MAPK) in response to particular growth factors (Gale et al., 1993) . A recent report demonstrated successful use of a MEK enzyme inhibitor CI-1040 as a chemotherapeutic agent to treat non-small-cell lung, breast, colon and pancreatic cancer. PD0325901, a second generation MEK inhibitor, has recently entered clinical development with better therapeutic potential for MEK inhibition in cancer (Rinehart et al., 2004) . Therefore, the identification of HOXA1 regulation of components of the p44/42 MAP kinase pathway further substantiates the oncogenic potential of HOXA1. In immortalized human mammary epithelial cells, forced expression of HOXA1 resulted in a dramatic increase in anchorage-independent proliferation, primarily by the promotion of cell survivalmediated by the transcriptional upregulation of Bcl-2 (Zhang et al., 2003) . We have demonstrated that HOXA1-stimulated upregulation of Bcl-2 is mediated by p44/42 MAP kinase pathway. Previous studies have also demonstrated that Bcl-2 upregulation occurs through the p44/42 MAP kinase pathway, resulting in increased cell survival (Wang et al., 2005) . Distinct from transcriptional upregulation of Bcl-2, p44/42 MAP kinase pathway also phosphorylates Bcl-2 at Ser-70. Increases in Bcl-2 phosphorylation results in cell survival by stabilization of Bcl-2:Bax interaction ( Ruvolo et al., 2001) . Activation of p44/42 MAP kinase could potentially target other signalling molecules, including signal transducer and activator of transcription (STAT), notably STAT3 and STAT5, which cooperate to confer the complete oncogenic potency of HOXA1 (manuscript in preparation; KM Mohankumar and PE Lobie, unpublished observations). Activated STAT3 and STAT5 pathways have also been reported to increase Bcl-2 expression levels (Lord et al., 2000; Hattori et al., 2001) . Thus, increased HOXA1-mediated Bcl-2 upregulation could be mediated directly through the activation of p44/42 MAP kinase and indirectly via p44/42 MAP kinase regulation of STAT3/5-mediated transcription.
In conclusion, we have demonstrated that HOXA1 in human mammary carcinoma cells results in increased p44/42 MAP kinase activity by virtue of increasing GRB2 and MEK1 expression. This increased p44/42 MAP kinase activity is required for HOXA1-stimulated cell proliferation, survival and oncogenicity.
Materials and methods
Cell culture MCF-7, MCF-10A, HBL100, T47D, ZR75-1, HS578T, SkBr3, 21MT, 21PT, MDA-MB-231, MDA-MB-435 and MDA-MB-468 cell lines were cultured using ATCC recommended conditions. MCF-7 and MCF-10A cell lines were stably transfected with either HOXA1 expression plasmid (pCMV Tag2B-HOXA1) or the empty vector (pCMV Tag2B). Stable cell lines MCF-7-vector, MCF-7-HOXA1, MCF-10A-vector and MCF-10A-HOXA1 were established using methods as described (Zhang et al., 2003) .
The design of siRNA vector targeting HOXA1 has been described by Zhu et al. (2005a) . The MCF-7 cell lines stably transfected with the HOXA1 siRNA construct (pSilencer-HOXA1) or the empty vector (scrambled siRNA), were named MCF-7-HOXA1 siRNA and MCF-7-scrambled-siRNA, respectively.
Microarray analysis
Total RNA was isolated from MCF-7-scrambled-siRNA, MCF-7-HOXA1 siRNA, MCF-7-vector, MCF-7-HOXA1, MCF-10A-vector and MCF-10A-HOXA1 cells using TRIZOL reagent.
Microarray analyses were performed as described previously (Xu et al., 2005) . HOXA1-upregulated genes were identified as those showing a X1.5-fold increase in cells with HOXA1 overexpression, but X1.5-fold decrease in HOXA1-depleted cells, whereas downregulated genes were identified as genes showing a X1.5-fold decrease in cells with HOXA1 overexpression, but a X1.5-fold increase in HOXA1 depleted cells.
RT-PCR and primers
Semiquantitative RT-PCRs were performed for the following genes as described (Mertani et al., 2001) . The sequences of the primers used are listed as Supplementary data 5.
Western blot analysis Cells were treated as described above and Western blot analysis was performed as described (Mertani et al., 2001) , using the following antibodies: anti-b-actin, anti-GRB2, anti-ERK-2 antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-MEK1 antibody and phospho p44/42 MAP kinase were from Cell Signaling Technology (Beverly, MA, USA).
p44/42 MAP kinase assay Cells were grown to 80% confluence in complete media for 24 h, and p44/42 MAP kinase assay was performed according to the protocol as described (Zhu et al., 2005b) .
Luciferase reporter assay
Cells were cultured to 40-60% confluence in six-well plates. Transient transfection with EphA2-r42B, Egr-3 and Elk-1 luciferase reporter constructs were performed by using SAINT MIX according to the manufacturer's instructions. Reporter assay was performed according to the protocol described previously (Zhu et al., 2005b) .
Cell number and oncogenicity assays 5 Â 10 4 of MCF-7-vector and MCF-7-HOXA1 cells were seeded into six-well plates in monolayers in complete media. Cell number was determined as previously described 720 mM MEK1 inhibitor, PD098059 (Zhu et al., 2005a) . 0.2 Â 10 6 of MCF-7-vector and MCF-7-HOXA1 cells were seeded in six-well plates and allowed to grow in complete medium. Cells were treated 720 mM PD098059 in fresh complete media for an additional 24 h. BrdU incorporation and detection was performed as previously described 720 mM PD098059 (Zhu et al., 2005a) .
Apoptotic cell death was determined as described previously 720 mM PD098059 (Mertani et al., 2001) .
Anchorage-independent growth assays, including suspension culture, were performed as previously described 720 mM PD098059 (Zhang et al., 2003) .
Morphogenesis assays
The 3D culture of MCF-10A cells in basement membrane was performed as described previously (Zhu et al., 2005a) . For studying MEK1 inhibitor, morphogenesis assays were performed with 10 mM PD098059. Immunostaining and image acquisition of acinar structures was performed as described (Zhu et al., 2005a) .
